Announcements Trials

Browse Landscape

Phase

Status

Unknown 2 Recruiting 2 Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 10 Congenital Abnormalities 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Leukemia, Myelomonocytic, Acute 3 Leukemia, Monocytic, Acute 3 Leukemia, Erythroblastic, Acute 3 Leukemia 3 Leukemia, Megakaryoblastic, Acute 2 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Eosinophilic, Acute 1 Leukemia, Basophilic, Acute 1 Carcinoma, Hepatocellular 1 Blast Crisis 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Sorafenib 29 Nivolumab 15 pembrolizumab 12 Radiosurgery 9 Bevacizumab 9 atezolizumab 7 regorafenib 5 Radiotherapy 5 Fluorouracil 5 Doxorubicin 5 lenvatinib 4 Sunitinib 4 Oxaliplatin 4 Ipilimumab 4 Gemcitabine 4 Ethiodized Oil 4 Erlotinib Hydrochloride 4 Capecitabine 4 TLC 388 3 Radiofrequency Ablation 3 Leucovorin 3 Everolimus 3 Cisplatin 3 Blood Specimen Collection 3 toripalimab 2 phosphomannopentaose sulfate 2 durvalumab 2 cediranib 2 avelumab 2 Tirapazamine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Hepatocellular × Idarubicin × Clear all

NCT03727633 2026-03-31

LIDA-BII

University Hospital, Montpellier

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡